Tóth I - Search Results

1

The intersubunit region of the influenza virus haemagglutinin is recognized by antibodies during infection.

Nagy Z, Rajnavölgyi E, Hollósi M, Tóth GK, Váradi G, Penke B, Tóth I, Horváth A, Gergely J, Kurucz I. Nagy Z, et al. Among authors: toth gk, toth i. Scand J Immunol. 1994 Sep;40(3):281-91. doi: 10.1111/j.1365-3083.1994.tb03464.x. Scand J Immunol. 1994. PMID: 8091127

2

Spectroscopy and modelling of the cytoplasmic domain of the gamma-subunit of the high affinity immunoglobulin E receptor.

Anderson GJ, Biekofsky RR, Zloh M, Toth GK, Toth I, Benedetti E, Gibbons WA. Anderson GJ, et al. Among authors: toth gk, toth i. Biomed Pept Proteins Nucleic Acids. 1994-1995;1(1):31-8. Biomed Pept Proteins Nucleic Acids. 1994. PMID: 9346867

3

Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.

Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, Good MF. Olive C, et al. Among authors: toth i. Vaccine. 2005 Mar 18;23(17-18):2298-303. doi: 10.1016/j.vaccine.2005.01.041. Vaccine. 2005. PMID: 15755615

4

A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Olive C, Batzloff MR, Horváth A, Wong A, Clair T, Yarwood P, Toth I, Good MF. Olive C, et al. Among authors: toth i. Infect Immun. 2002 May;70(5):2734-8. doi: 10.1128/IAI.70.5.2734-2738.2002. Infect Immun. 2002. PMID: 11953422 Free PMC article.

5

Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.

Olive C, Batzloff M, Horváth A, Clair T, Yarwood P, Toth I, Good MF. Olive C, et al. Among authors: toth i. Infect Immun. 2003 May;71(5):2373-83. doi: 10.1128/IAI.71.5.2373-2383.2003. Infect Immun. 2003. PMID: 12704107 Free PMC article.

6

Sequence-specific anti-peptide antibodies that recognize different subunits of the high-affinity IgE receptor.

Gao B, Anderson GJ, Brammer MJ, James CH, Danton M, Toth G, Toth I, Gibbons WA. Gao B, et al. Among authors: toth g, toth i. Biochem Soc Trans. 1993 May;21(2):302-4. doi: 10.1042/bst0210302. Biochem Soc Trans. 1993. PMID: 8359486 No abstract available.

7

Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.

Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, Toth I, Guzman CA. Olive C, et al. Among authors: toth i. Vaccine. 2007 Feb 26;25(10):1789-97. doi: 10.1016/j.vaccine.2006.11.031. Epub 2006 Nov 30. Vaccine. 2007. PMID: 17229503

8

Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.

Horváth A, Olive C, Karpati L, Sun HK, Good M, Toth I. Horváth A, et al. Among authors: toth i. J Med Chem. 2004 Jul 29;47(16):4100-4. doi: 10.1021/jm040041w. J Med Chem. 2004. PMID: 15267249

9

Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes.

Horvath A, Olive C, Wong A, Clair T, Yarwood P, Good M, Toth I. Horvath A, et al. Among authors: toth i. J Med Chem. 2002 Mar 14;45(6):1387-90. doi: 10.1021/jm0110441. J Med Chem. 2002. PMID: 11882009

10

Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.

Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF. Olive C, et al. Among authors: toth i. J Infect Dis. 2006 Aug 1;194(3):316-24. doi: 10.1086/505580. Epub 2006 Jun 30. J Infect Dis. 2006. PMID: 16826479

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,010 results

Search Page

Filters